KOSDAQElectronic Components199550

Laseroptek

₩2,825▲ 0.18%2026-11-18 close
Market Cap
₩41.9B
Turnover
₩76,216,645
Volume
30K
Shares out.
14.9M
PER
—
PBR
1.2×
EPS
-₩537
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses narrowing, but sustained profitability not yet confirmed

Laseroptek's operating loss in the third quarter of 2026 was KRW 341 million, the smallest of the last five quarters, but the full-year 2025 operating loss of KRW 12 billion means a return to profit is not yet confirmed.

  1. 1

    Revenue fell 22.2% year on year to KRW 25.7 billion in 2025, and the operating loss widened to KRW 12 billion.

  2. 2

    The operating loss narrowed to KRW 341 million in the third quarter of 2026, but the net loss attributable to controlling shareholders was KRW 2.63 billion, larger than the operating loss.

  3. 3

    Overseas sales are growing fast, led by Latin America, where cumulative third-quarter 2026 sales reached KRW 1.66 billion, up 368.8% year on year, according to press reports.

  4. 4

    Approval of VASCURA 589 by the U.S. FDA is being pursued, with a target of the first quarter of 2027.

  5. 5

    Litigation with a U.S. competitor, ongoing since 2024, has moved to the merits trial stage.

02

Business structure

Laseroptek is a specialist maker of laser devices used for skin aesthetics and the treatment of medical conditions. In a February 2026 interview, the company's CEO said the current revenue mix is about 80% aesthetics and 20% medical treatment, with a medium-to-long-term goal of raising the treatment share to 40%.

Its flagship pigment laser, 'HELIOS 785 PICO', recorded cumulative third-quarter 2026 sales of KRW 7.35 billion, up about KRW 2.1 billion from the prior-year period, according to press reports.

The 'LOTUS III' erbium:YAG laser, combined with a needle-free drug delivery system, posted cumulative sales of KRW 3.5 billion, up 63.1%. VASCURA 589, a 589-nanometer solid-state vascular laser launched in June 2026, targets vascular skin conditions such as hemangiomas as well as cosmetic procedures.

By region, cumulative third-quarter 2026 domestic sales were KRW 11.86 billion (up 32.9%), European sales KRW 2.26 billion (up 17.1%) and Latin American sales KRW 1.66 billion (up 368.8%).

In Brazil, the company holds an exclusive partnership with the local firm ENTERA and has secured health-regulator approval for three core products.

Domestic customers are mainly dermatology and plastic surgery clinics, and the company has built a direct sales network in western U.S. states and Texas and expanded into Canada. Litigation with a U.S. competitor that began in 2024 has moved to the merits trial stage and has weighed on U.S. revenue.

The structure therefore combines aesthetic equipment and consumables with distributor-led overseas sales, and broadening into medical treatment is the key test of revenue diversity.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩9.9B-₩3B−30.1%
2025Q4₩6.7B-₩4.5B−67.5%
2026Q1₩6.4B-₩2B−30.7%
2026Q2₩8.8B-₩1B−11.3%
2026Q3₩7.2B-₩300M−4.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩30B₩2.5B₩2.8B8.4%23.4%108.9%
2023₩34.4B₩4.5B₩16,781,54313.0%0.1%48.5%
2024₩33B-₩200M-₩800M−0.6%−2.6%48.9%
2025₩25.7B-₩12B-₩10.7B−46.9%−48.4%64.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue rose from KRW 30 billion in 2022 to KRW 34.4 billion in 2023, a 14.3% increase, which marks the peak year. Revenue then declined 3.8% to KRW 33 billion in 2024 and fell 22.2% to KRW 25.7 billion in 2025, so revenue decreased for two consecutive years from 2024 through 2025.

Among 2022 to 2025, 2023 was the largest year and 2025 the smallest. Operating profit reached KRW 4.48 billion in 2023, up 78.5%, before turning into an operating loss of KRW 196 million in 2024, and the operating loss widened to KRW 12 billion in 2025.

The operating margin moved from 8.4% in 2022 and 13.0% in 2023 to -0.6% in 2024 and -46.9% in 2025.

Net profit attributable to controlling shareholders fell 99.4% to KRW 16.78 million in 2023, then became a net loss of KRW 783 million in 2024 and KRW 10.7 billion in 2025, which is two consecutive years of losses from 2024 through 2025.

Net income including non-controlling interests was a net loss of KRW 10.7 billion in 2025. Operating cash flow went from KRW 1.44 billion in 2022 to -KRW 196 million in 2023, -KRW 3.34 billion in 2024 and -KRW 6.39 billion in 2025.

A half-year 2025 press report pointed to lower U.S. revenue during litigation with a U.S. competitor, and to delayed Middle East shipments that pushed some sales into the third quarter.

On a five-quarter basis, third-quarter 2025 revenue of KRW 9.87 billion was the highest, and third-quarter 2026 revenue was KRW 7.22 billion, down 26.9% year on year.

Operating losses narrowed from KRW 2.97 billion in the third quarter of 2025 and KRW 4.49 billion in the fourth quarter to KRW 1.95 billion, KRW 991 million and KRW 341 million across the first three quarters of 2026. This extends five consecutive quarters of operating losses, while the size of the losses is shrinking.

By contrast, the net loss attributable to controlling shareholders in the third quarter of 2026 was KRW 2.63 billion, up from KRW 772 million in the second quarter and larger than the operating loss.

The four-quarter total of net losses attributable to controlling shareholders, from the fourth quarter of 2025 through the third quarter of 2026, was KRW 7.13 billion.

The company said cumulative third-quarter 2026 selling and administrative expenses fell 8.7% and bad-debt expense dropped sharply, which helped narrow the operating loss.

05

Industry analysis

Laseroptek sits in the electronics and components sector by classification, but its business is closer to medical devices. Laser demand for skin aesthetics and for medical treatment of skin conditions moves with both consumer beauty spending and clinic treatment demand.

In a January 2026 press report, the company said demand for high-power vascular lasers in the global skin-condition treatment and medical aesthetics market has been rising steadily. This is the company's own market view.

In the U.S., litigation with a competitor and the insurance code framework shape the operating environment. The company said the insurance code framework is being settled in a direction favorable to it.

Asia sales in the first half of 2026 were KRW 4.6 billion, up 101.9% year on year, supported by dual distributors and wider sales channels in Japan and the Middle East. In the first half of 2025, revenue fell 50.9%, which the company attributed mainly to the U.S. litigation and delayed Middle East shipments.

That pattern suggests reported results have moved more with company-specific litigation and geopolitical factors than with sector-wide conditions. Growth in the skin-booster market was cited as a driver of LOTUS III sales.

Competitive position depends on product differentiation, such as the 589-nanometer solid-state vascular laser and the needle-free drug delivery combination line, and on the outcome of the U.S. litigation.

06

Outlook

Fourth-quarter 2026 results will first be disclosed in the 2026 annual report. In its third-quarter 2026 release, the company said it aims to keep improving results in the fourth quarter.

VASCURA 589 was launched in June 2026, and the company plans to expand sales in the second half of 2026 and grow exports of its core products. U.S. FDA approval is being pursued with a target of the first quarter of 2027, and approval would determine the timing of entry into North America.

The company expects the local sales environment to improve if U.S. litigation risk eases and insurance code changes become visible, possibly as early as the first quarter of 2027.

In overseas markets, the company changed its distributor in Brazil, secured new supply contracts and opened a direct office to strengthen sales and customer support. The company has set a medium-to-long-term goal of raising the medical-treatment share of revenue to 40%.

On funding, the KRW 11.7 billion rights offering decided in February 2026 is reported to be allocated to raw material procurement, new product development, overseas certification and clinical work, and marketing. These plans are the company's own statements, and their effect will show up in later disclosed results.

07

Valuation

PER
—
PBR
1.2×
ROE
-26.8%
EPS
-₩537
BPS
₩2,320
Dividend per share
₩0

The price-to-book ratio is above 1x, meaning the share price is trading above book value. Total equity at the end of 2025 was KRW 22.2 billion, all of it attributable to controlling shareholders, and total liabilities were KRW 14.4 billion. The debt-to-equity ratio rose from 48.9% in 2024 to 64.8% in 2025.

PER cannot be calculated because the last four quarters were net losses, so the share price cannot be compared with earnings on a multiple basis. The dividend yield is effectively nil, leaving little cash return through dividends. The rights offering decided in February 2026 adds to equity.

Earnings-based multiples do not apply while the company is loss-making, so the share price is explained mainly by its relation to book value and the trend in operating results.

Because the operating loss narrowed to KRW 341 million in the third quarter of 2026, earnings-based indicators could be recalculated if the company moves into profit.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Recovery in overseas sales

Cumulative third-quarter 2026 Latin American sales reached KRW 1.66 billion, up 368.8% year on year, and European sales rose 17.1%. In Brazil, the company holds an exclusive partnership with ENTERA and has secured approvals for three core products. First-half 2026 Asia sales of KRW 4.6 billion, up 101.9%, show sales regions broadening.

Narrowing operating losses

Operating losses fell from KRW 4.49 billion in the fourth quarter of 2025 to KRW 1.95 billion, KRW 991 million and KRW 341 million across the first three quarters of 2026. Cumulative third-quarter 2026 selling and administrative expenses fell 8.7%, and bad-debt expense dropped sharply. The operating margin remains negative, but the narrowing trend has held across the recent quarters.

New products and expansion into medical treatment

VASCURA 589, a vascular laser launched in June 2026, targets vascular skin conditions as well as cosmetic procedures. The company has set a goal of raising the medical-treatment share of revenue to 40% over the medium to long term. Its U.S. FDA approval target is the first quarter of 2027, and approval would allow entry into North America.

09

Bear factors

Deterioration in 2025 results

Revenue fell 22.2% to KRW 25.7 billion in 2025, the operating loss widened to KRW 12 billion, and the operating margin dropped to -46.9%. The net loss attributable to controlling shareholders was KRW 10.7 billion, following 2024 as a second consecutive year of losses.

Profitability has deteriorated sharply since the KRW 4.48 billion operating profit in 2023, which is the largest bearish factor.

Non-operating items and cash flow

The net loss attributable to controlling shareholders in the third quarter of 2026 was KRW 2.63 billion, larger than the KRW 341 million operating loss. The four-quarter total of such net losses reached KRW 7.13 billion. Operating cash flow also widened to -KRW 6.39 billion in 2025.

Litigation burden and reliance on capital raising

Litigation with a U.S. competitor, ongoing since 2024, has reached the merits trial stage and has weighed on U.S. revenue. A KRW 11.7 billion rights offering was decided in February 2026, and the debt-to-equity ratio rose to 64.8% in 2025 from 48.9% in 2024. Dependence on outside funding remains a bearish factor.

10

Risk factors

Legal and regulatory risk

Litigation with a U.S. competitor is at the merits trial stage, and its outcome could change local U.S. operations. Whether insurance code changes become visible after the first quarter of 2027 remains open. The first quarter of 2027 is the company's target for FDA approval of VASCURA 589, not a confirmed date.

Financial and funding risk

Operating cash flow has been negative since 2023, reaching -KRW 6.39 billion in 2025. The debt-to-equity ratio rose to 64.8% in 2025, and the February 2026 rights offering shows reliance on outside funding. Whether cash generation improves is the central question for financial risk.

Currency and geopolitical risk

Foreign currency valuation gains and losses have been reported as a factor that moves net results differently from operating results. In the first half of 2025, delayed Middle East shipments pushed some sales into the third quarter. As overseas revenue grows, exchange rates and international conditions can add to earnings volatility.

11

What to watch next

  1. First quarter of 2027 (company target)

    Whether VASCURA 589 receives U.S. FDA approval. Approval would set the timing of North American entry, while a delay would slow the planned expansion of overseas sales.

  2. After the first quarter of 2027 (company expectation)

    The outcome of the U.S. litigation and whether insurance code changes become visible. These two factors determine the local U.S. operating environment and the scale of any sales recovery there.

  3. Around March 2027 (estimated from 2025 disclosure timing)

    The 2026 annual report, which will first disclose fourth-quarter and full-year 2026 revenue, operating results and operating cash flow. It is the point to check whether the narrowing operating loss carried through on an annual basis.

  4. Mid-May 2027 (based on the May 2026 release pattern)

    First-quarter 2027 results. The checkpoints are whether the operating result moves toward profit and whether the net loss attributable to controlling shareholders diverges from the operating result due to non-operating items.

12

Overall view

Laseroptek moved through a second consecutive year of losses in 2025, with revenue of KRW 25.7 billion and an operating loss of KRW 12 billion. In the third quarter of 2026, the operating loss narrowed to KRW 341 million, the smallest of the last five quarters.

Overseas, cumulative third-quarter 2026 Latin American sales rose 368.8%, and the medical-treatment product VASCURA 589 was launched in June 2026.

Against that, the net loss attributable to controlling shareholders in the same quarter was KRW 2.63 billion, larger than the operating loss, and the four-quarter total reached KRW 7.13 billion. Operating cash flow widened to -KRW 6.39 billion in 2025, and the debt-to-equity ratio rose to 64.8%.

A KRW 11.7 billion rights offering was decided in February 2026. The U.S. litigation is at the merits trial stage, and the company targets FDA approval of VASCURA 589 in the first quarter of 2027.

The next checkpoints are the operating result and operating cash flow in the 2026 annual report, and the FDA decision and litigation outcome in the first quarter of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. ebn.co.kr
  2. kr.investing.com
  3. rapportian.com
  4. bokuennews.com
  5. ebn.co.kr
  6. newstap.co.kr
  7. newspim.com
  8. m.news.nate.com
  9. pharmnews.com
  10. m.news.nate.com
  11. paxetv.com
  12. news.nate.com
  13. news.nate.com
  14. investing.com
  15. busan.fnnews.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis